ATE330598T1 - Behandlung von krebs durch erhöhung des malonyl- coa-spiegels - Google Patents
Behandlung von krebs durch erhöhung des malonyl- coa-spiegelsInfo
- Publication number
- ATE330598T1 ATE330598T1 AT00978553T AT00978553T ATE330598T1 AT E330598 T1 ATE330598 T1 AT E330598T1 AT 00978553 T AT00978553 T AT 00978553T AT 00978553 T AT00978553 T AT 00978553T AT E330598 T1 ATE330598 T1 AT E330598T1
- Authority
- AT
- Austria
- Prior art keywords
- fatty acid
- inhibition
- cpt
- fas
- malonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16476899P | 1999-11-12 | 1999-11-12 | |
US16476599P | 1999-11-12 | 1999-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE330598T1 true ATE330598T1 (de) | 2006-07-15 |
Family
ID=26860829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00978553T ATE330598T1 (de) | 1999-11-12 | 2000-11-13 | Behandlung von krebs durch erhöhung des malonyl- coa-spiegels |
Country Status (12)
Country | Link |
---|---|
US (1) | US20020187534A1 (de) |
EP (1) | EP1227810B8 (de) |
JP (1) | JP2003513920A (de) |
KR (4) | KR20090031957A (de) |
AT (1) | ATE330598T1 (de) |
AU (3) | AU784495B2 (de) |
CA (1) | CA2391277A1 (de) |
DE (1) | DE60028996T2 (de) |
DK (1) | DK1227810T3 (de) |
ES (1) | ES2267587T3 (de) |
PT (1) | PT1227810E (de) |
WO (1) | WO2001034145A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322929B1 (de) * | 2000-11-27 | 2016-04-06 | Minerva Biotechnologies Corporation | Diagnostika, Drogenscreening und Behandlung für Krebs |
WO2003037323A2 (en) * | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction |
AU2003215111A1 (en) | 2002-02-08 | 2003-09-02 | The Johns Hopkins University School Of Medicine | Stimulation of cpt-1 as a means to reduce weight |
BRPI0312413A2 (pt) * | 2002-07-01 | 2016-08-02 | Fasgen Llc | compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos |
MXPA05004390A (es) * | 2002-10-31 | 2005-11-23 | Fasgen Llc | Metodo para inhibicion del desarrollo del cancer por inhibidores de la sintasa de acidos grasos. |
CA2515368A1 (en) | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
EP2377528B1 (de) * | 2003-06-12 | 2014-02-19 | The Board of Regents of the University of Colorado | Fettsäure-Stoffwechsel-Hemmer zur Verwendung in der Behandlung von Krebs |
US7510710B2 (en) | 2004-01-08 | 2009-03-31 | The Regents Of The University Of Colorado | Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
ITMI20040230A1 (it) * | 2004-02-12 | 2004-05-12 | Defiante Farmaceutica Lda | Composti ad attivita' antitumorale |
CA2611735A1 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of Colorado | Therapeutic bifunctional compounds |
US8329753B2 (en) | 2005-05-02 | 2012-12-11 | The Regents Of The University Of Colorado | Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition |
EP2018873A4 (de) * | 2006-04-07 | 2009-12-09 | Japan Found Cancer | Mittel zur prophylaxe/behandlung von krebs |
WO2008106796A1 (en) * | 2007-03-08 | 2008-09-12 | University Health Network | Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity |
CA2680366C (en) | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
EP3048168A1 (de) * | 2007-07-27 | 2016-07-27 | Vesta Therapeutics, Inc. | Verfahren zur reduzierung intrazellulärer fette aus säugerzellen |
WO2009015485A1 (en) * | 2007-08-01 | 2009-02-05 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
US8394377B2 (en) | 2008-02-21 | 2013-03-12 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
US9073985B2 (en) | 2008-07-14 | 2015-07-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods and products for treating proliferative diseases |
JP5317919B2 (ja) * | 2009-10-05 | 2013-10-16 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗muc1* 抗体 |
CA3040637C (en) * | 2016-10-17 | 2023-02-28 | Keio University | Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells |
WO2020212362A1 (en) * | 2019-04-15 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method of profiling the energetic metabolism of a population of cells |
CN113604573A (zh) * | 2021-09-14 | 2021-11-05 | 北京大学第三医院(北京大学第三临床医学院) | 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒 |
CN113549702A (zh) * | 2021-09-14 | 2021-10-26 | 北京大学第三医院(北京大学第三临床医学院) | 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759837A (en) * | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
WO1994002108A1 (en) * | 1992-07-24 | 1994-02-03 | The Johns Hopkins University | Chemotherapy for cancer |
US5539132A (en) * | 1994-01-24 | 1996-07-23 | Johns Hopkins University | Cerulenin compounds for fatty acid synthesis inhibition |
US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
-
2000
- 2000-11-13 DE DE60028996T patent/DE60028996T2/de not_active Expired - Fee Related
- 2000-11-13 EP EP00978553A patent/EP1227810B8/de not_active Expired - Lifetime
- 2000-11-13 WO PCT/US2000/031067 patent/WO2001034145A1/en active IP Right Grant
- 2000-11-13 CA CA002391277A patent/CA2391277A1/en not_active Abandoned
- 2000-11-13 AT AT00978553T patent/ATE330598T1/de not_active IP Right Cessation
- 2000-11-13 JP JP2001536143A patent/JP2003513920A/ja active Pending
- 2000-11-13 ES ES00978553T patent/ES2267587T3/es not_active Expired - Lifetime
- 2000-11-13 AU AU16007/01A patent/AU784495B2/en not_active Ceased
- 2000-11-13 KR KR1020097004579A patent/KR20090031957A/ko not_active Application Discontinuation
- 2000-11-13 KR KR1020027006097A patent/KR20020060736A/ko not_active Application Discontinuation
- 2000-11-13 PT PT00978553T patent/PT1227810E/pt unknown
- 2000-11-13 DK DK00978553T patent/DK1227810T3/da active
- 2000-11-13 KR KR1020097024726A patent/KR20090130151A/ko not_active Application Discontinuation
- 2000-11-13 KR KR1020077023100A patent/KR20070106648A/ko not_active Application Discontinuation
-
2002
- 2002-05-10 US US10/141,859 patent/US20020187534A1/en not_active Abandoned
-
2006
- 2006-07-13 AU AU2006203005A patent/AU2006203005A1/en not_active Abandoned
-
2009
- 2009-10-16 AU AU2009227836A patent/AU2009227836A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1227810T3 (da) | 2006-10-23 |
EP1227810B1 (de) | 2006-06-21 |
PT1227810E (pt) | 2006-11-30 |
KR20070106648A (ko) | 2007-11-02 |
EP1227810A1 (de) | 2002-08-07 |
CA2391277A1 (en) | 2001-05-17 |
DE60028996D1 (de) | 2006-08-03 |
WO2001034145A1 (en) | 2001-05-17 |
KR20090130151A (ko) | 2009-12-17 |
US20020187534A1 (en) | 2002-12-12 |
KR20090031957A (ko) | 2009-03-30 |
EP1227810B8 (de) | 2006-08-16 |
ES2267587T3 (es) | 2007-03-16 |
DE60028996T2 (de) | 2007-02-08 |
AU1600701A (en) | 2001-06-06 |
KR20020060736A (ko) | 2002-07-18 |
AU784495B2 (en) | 2006-04-13 |
AU2006203005A1 (en) | 2006-08-10 |
JP2003513920A (ja) | 2003-04-15 |
AU2009227836A1 (en) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE330598T1 (de) | Behandlung von krebs durch erhöhung des malonyl- coa-spiegels | |
Morris et al. | Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning | |
Halsall et al. | Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success | |
Gao et al. | Stress granule: a promising target for cancer treatment | |
Abboud et al. | Antitumor action of amygdalin on human breast cancer cells by selective sensitization to oxidative stress | |
Baek et al. | Sesamol decreases melanin biosynthesis in melanocyte cells and zebrafish: Possible involvement of MITF via the intracellular cAMP and p38/JNK signalling pathways | |
Carrasco‐Pozo et al. | Sulforaphane is anticonvulsant and improves mitochondrial function | |
ATE509014T1 (de) | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren | |
Liu et al. | Hydrogen sulfide signaling axis as a target for prostate cancer therapeutics | |
ATE487475T1 (de) | Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer | |
NO20033665L (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
ATE341539T1 (de) | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren | |
DE602004009582D1 (de) | Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer | |
BR0206400A (pt) | Compostos de amino ceramidas e seus usos em métodos terapêuticos | |
Velmurugan et al. | Excavatolide B inhibits nonsmall cell lung cancer proliferation by altering peroxisome proliferator activated receptor gamma expression and PTEN/AKT/NF‐Kβ expression | |
Chen et al. | Antiphotoaging effect of boiled abalone residual peptide ATPGDEG on UVB-induced keratinocyte HaCaT cells | |
Coronel-Hernández et al. | Aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities | |
Wang et al. | Apigenin inhibits human SW620 cell growth by targeting polyamine catabolism | |
EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) | |
EA200500958A1 (ru) | Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения | |
Shatanawi et al. | Arginase inhibition suppresses breast cancer cell proliferation | |
Chaudhary et al. | Effect of acute hypobaric hypoxia on skeletal muscle protein turnover | |
DK1565176T3 (da) | Middel med ödelæggende virkning på maligne rumorer samt fremgangsmåde til fremstilling heraf | |
Zhang et al. | N‐acetyl‐cysteine enhances growth in BCR‐ABL‐transformed cells | |
Dando et al. | New Insights into Metabolic Alterations and Mitochondria Re-Arrangements in Pancreatic Adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1227810 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |